Brief: Eledon Pharmaceuticals Inc Reports Net Loss Of $58.4 Million, Or $4.09 Per Share, For Three Months Ended December 31, 2022
30/03/2023 21:15
March 30 (Reuters) - Eledon Pharmaceuticals Inc
ELDN.O :
* ELEDON PHARMACEUTICALS REPORTS FOURTH QUARTER AND
FULL-YEAR 2022
OPERATING AND FINANCIAL RESULTS
* NET LOSS OF $58.4 MILLION, OR $4.09 PER SHARE, FOR THREE
MONTHS
ENDED DECEMBER 31, 2022
* CASH AND CASH EQUIVALENTS WILL BE SUFFICIENT TO SUSTAIN
OPERATIONS INTO Q1 OF 2024
* Q4 EARNINGS PER SHARE VIEW $-0.70 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX24bKCG
Further company coverage: ELDN.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Eledon Pharmaceuticals
See all newsBrief: Eledon Presents Updated Long-Term Phase 2 Bestow Extension Study Results At The International Congress Of The Transplantation Society
Eledon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Eledon Pharmaceuticals Q2 net loss widens on warrant liability changes
Eledon Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Natera And Eledon Announce Strategic Partnership For Prospera™ Monitoring In Planned Phase 3 Kidney Transplant Trial